Filters
Results 1 - 10 of 6099
Results 1 - 10 of 6099.
Search took: 0.03 seconds
Sort by: date | relevance |
AbstractAbstract
[en] The focus of the Symposium was on basic problems which can interfer with clinical applications of monoclonal antibodies. The importance of technical factors in both producing the antibodies, and in subsequently radiolabeling these antibody preparations were discussed. Throughout all of these preparatory steps, it is important to keep in mind that the immunoactivity of the antibody must be retained at all costs. The importance of developing new methods which would allow for larger amounts of specific high quality antibody to the prepared were stressed. The importance of this was emphasized in that dose parameters and dose studies currently underway at the time of the meeting, indicated that larger doses of Fab were more effective in targeting tumor than smaller doses. All of the participants agreed that the potential applicability of this technique was very great. Highly tumor-specific monoclonal antibodies have been developed against virtually all the common solid tumors of major clinical importance in man. These include colon, breast, lung, and melanoma. Prostate and lymphatic tissue, also had specific antibodies developed against them. A major factor in determining the success of this technique in the future will be overcoming important technical barriers to the targeting of these radiolabeled antibodies to tumors. These barriers include the difficulty in producing large quantities of radiolabeled immunoactive antibodies
Primary Subject
Secondary Subject
Source
1984; 4 p; American College of Nuclear Physicians annual meeting; San Diego, CA (USA); 19 Feb 1984; CONF-8402159--PT.1-SUMM; Available from NTIS, PC A02/MF A01; 1 as DE86002287; Portions of this document are illegible in microfiche products.
Record Type
Report
Literature Type
Conference
Report Number
Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
AbstractAbstract
[en] Reduction of disulfide bonds to sulfhydryl (SH) groups for direct radiolabeling of antibodies for immunoscintigraphic studies of colorectal and other cancers continues to be of considerable research interest. We have developed a general strategy and a versatile computer program for the quantification of the number of SH per molecule of antibody (Ab) generated after the treatment of monoclonal antibodies (MAbs) with reducing agents such as 2-mercaptoethanol (2-ME), stannous chloride (SnCl2), dithiothreitol (DTT), dithioerythritol (DTE), ascorbic acid (AA), and the like. The program we describe here performs an unweighted least-squares regression analysis of the cysteine standard curve and interpolates the cysteine concentration of the samples. The number of SH groups per molecule of antibody in the 2-mercaptoethanol and in the other reducing agents was calculated from the cysteine standard curve using Ellman's reagent to develop the yellow color. The linear least-squares method fit the standard data with a high degree of accuracy and with the correlation coefficient r of 0.999. A program has been written for the IBM PC compatible computer utilizing a friendly menu to interact with the users. The package allows the user to change parameters of the assay, to calculate regression coefficients slope, intercept and its standard errors, to perform statistical analysis, together with detailed analysis of variance, and to produce an output of the results in a printed format
Primary Subject
Source
0969805196000273; Copyright (c) 1996 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
AbstractAbstract
[en] This book attempts to assemble literature relevant to the radiopharmacist and others in related disciplines. The scope of the book is broad, covering all areas from urology and hematology to cardiology and the central nervous system. in addition, it contains a 61-page explanation of the radiopharmacology of monoclonal antibodies. This book catalogues work from 1988
Primary Subject
Source
1988; 329 p; Gordon and Breach Science Publishers Inc; New York, NY (USA); Gordon and Breach Science Publishers, Inc., P.O. Box 786, Cooper Station, New York, NY 10276 (USA)
Record Type
Book
Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
AbstractAbstract
[en] Matrix metalloproteinases (MMPs), a group of more than 20 zinc-containing endopeptidases, are upregulated in many diseases, but several attempts to use radiolabelled MMP inhibitors for imaging tumours have proved unsuccessful in mouse models, possibly due to the limited specificity of these agents or their unfavourable pharmacokinetic profiles. In principle, radiolabelled monoclonal antibodies could be considered for the selective targeting and imaging of individual MMPs. We cloned, produced and characterized high-affinity monoclonal antibodies specific to murine MMP-1A, MMP-2 and MMP-3 in SIP (small immunoprotein) miniantibody format using biochemical and immunochemical methods. We also performed comparative biodistribution analysis of their tumour-targeting properties at three time points (3 h, 24 h, 48 h) in mice bearing subcutaneous F9 tumours using radioiodinated protein preparations. The clinical stage L19 antibody, specific to the alternatively spliced EDB domain of fibronectin, was used as reference tumour-targeting agent for in vivo studies. All anti-MMP antibodies and SIP(L19) strongly stained sections of F9 tumours when assessed by immunofluorescence methods. In biodistribution experiments, SIP(SP3), specific to MMP-3, selectively accumulated at the tumour site 24 and 48 h after intravenous injection, but was rapidly cleared from other organs. By contrast, SIP(SP1) and SIP(SP2), specific to MMP-1A and MMP-2, showed no preferential accumulation at the tumour site. Antibodies specific to MMP-3 may serve as vehicles for the efficient and selective delivery of imaging agents or therapeutic molecules to sites of disease. (orig.)
Primary Subject
Source
Available from: http://dx.doi.org/10.1007/s00259-010-1446-9
Record Type
Journal Article
Journal
European Journal of Nuclear Medicine and Molecular Imaging; ISSN 1619-7070;
; v. 37(8); p. 1559-1565

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
AbstractAbstract
[en] This paper highlights the major obstacles and prospects of antibody targeting for the radio imaging and therapy of human malignant lymphomas and more challenging solid tumors. To improve the therapeutic potential of monoclonal antibodies, the authors have focused their attention on the development of new and successful methods to augment antibody uptake in the tumor. These approaches include the use of radiolabeled streptavidin to target biotinylated monoclonal antibodies already bound to tumor, pretreatment with vasoactive immunoconjugates, and the use of chemically modified antibodies. Because of the promising preclinical data obtained with these three newer approaches, plans are underway to test them in the clinic. More generally, these approaches are applicable to the use of other monoclonal antibody/tumor systems for the diagnosis and therapy of human cancers and related diseases
Primary Subject
Record Type
Journal Article
Journal
Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
AbstractAbstract
No abstract available
Primary Subject
Source
Namiestnik, J.; Gdaniec-Pietryka, M.; Klimaszewska, K.; Gorecka, A.; Sagajdakow, A.; Jakubowska, N. (Department of Analytical Chemistry, Chemical Faculty, Gdansk University of Technology - GUT, Gdansk (Poland)); International Association of Environmental Analytical Chemistry - IAEAC (International Atomic Energy Agency (IAEA)); the Committee on Analytical Chemistry of the Polish Academy of Science, Warsaw (Poland); Department of Analytical Chemistry, Chemical Faculty, Gdansk University of Technology, Gdansk (Poland); 372 p; ISBN 978-83-925754-4-3;
; 2008; p. 34-38; ISEAC 35: 35. International Symposium on Environmental Analytical Chemistry; Gdansk (Poland); 22-26 Jun 2008; Also available from Department of Analytical Chemistry, Chemical Faculty, Gdansk University of Technology - GUT, Gdansk (PL); also available from http://www.pg.gda.pl/chem/iaeac/book_of_abstracts.pdf; 12 refs., 4 figs.

Record Type
Miscellaneous
Literature Type
Conference
Report Number
Country of publication
Reference NumberReference Number
Related RecordRelated Record
INIS VolumeINIS Volume
INIS IssueINIS Issue
AbstractAbstract
[en] Spontaneous diseased animals decrease the number of experimental used. Chemicalien should have transgenerational effects. Reproductive organs are one of the most sensitive system for the pollution. Extended length of life increase the incidence of 'new' diseases. Felidae model for biotechnology and endangered species
Primary Subject
Source
International Atomic Energy Agency (IAEA), Vienna (Austria); Ministerio de Ciencia, Tecnología y Medio Ambiente (CITMA), La Habana (Cuba); Agencia de Energía Nuclear y Tecnologías de Avanzadas (AENTA), La Habana (Cuba); Ministerio de Salud Pública (MINSAP), La Habana (Cuba); Isotope Technologies Dresden (ITD), Dresden (Germany); Institute of Isotopes Co., Ltd. (IZOTOP), Budapest (Hungary); SPINREACT, Girona (Spain); Tema Sinergie, Faenza (Italy); Centro de Isotopos (CENTIS) , Mayabeque (Cuba); 1 CD-ROM; 5 Feb 2016; 4 MB; 5. International Seminar and 5. National Workshop 'Use and development of products isotopic health industry'. 20th anniversary CENTIS; Havana (Cuba); 3-5 Feb 2016
Record Type
Multimedia
Literature Type
Conference
Report Number
Country of publication
Reference NumberReference Number
Related RecordRelated Record
INIS VolumeINIS Volume
INIS IssueINIS Issue
AbstractAbstract
[en] A rapid, single vessel method for the preparation of clinical grade chelate conjugated monoclonal antibodies has been developed. By use of an Amicon concentrator with reservoir, each of the steps necessary for the preparation of the conjugated drug may be performed in a single vessel. Advantages include reduced risk of metal, pyrogen and bacterial contamination; buffer exchanges are achieved rapidly and efficiently using a continuous dilution method. The radiolabeling efficiency, the radiochemical purity, the total immunoreactivity and the affinity of the final product have been evaluated in the production of CHXA-DTPA-chelate conjugated HuM195. The characteristics compare favorably to those achieved using our conventional synthetic methods
Primary Subject
Source
Copyright (c) 1995 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
AbstractAbstract
[en] Rat monoclonal antibodies were prepared by immunising rats with human colorectal carcinoma cell membranes and fusing splenic lymphocytes with a rat myeloma. Hybridoma supernatants were screened by binding assays on membranes prepared from colorectal carcinoma tissue. One hybridoma supernatant, containing a monoclonal antibody with high binding activity on malignant compared to normal colon sections, was grown in large quantities in serum-free medium. After ammonium sulphate precipitation the antibody was purified by ion-exchange chromatography and labelled with 131I. Radiolabelled antibody was administered i.v. to 27 patients with colonic and other tumours. Scintigrams were obtained at 48 h. Computerised subtraction of the blood pool image revealed localised areas of uptake corresponding with areas of known disease in 13/16 patients with colorectal carcinoma and 3/4 patients with breast cancer. (author)
Primary Subject
Record Type
Journal Article
Journal
British Journal of Cancer; ISSN 0007-0920;
; v. 47(2); p. 253-259

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
AbstractAbstract
No abstract available
Primary Subject
Record Type
Journal Article
Literature Type
Progress Report
Journal
Nat. Inst. Anim. Health Quart. (Tokyo); v. 10(3-4); p. 143-150
Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
1 | 2 | 3 | Next |